Results 151 to 160 of about 35,110 (216)

Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer. [PDF]

Clin Transl Oncol, 2023
Xu X, Liu M, Peng K, Yu Y, Liu T.
europepmc   +1 more source

Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. [PDF]

, 2018
Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC).
Dicker, Adam P., Lu, Bo, McCall, Neal S.
core   +1 more source

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer. [PDF]

Cancers (Basel), 2022
Cserepes M, Nelhűbel GA, Meilinger-Dobra M, Herczeg A, Türk D, Hegedűs Z, Svajda L, Rásó E, Ladányi A, Csikó KG, Kenessey I, Szöőr Á, Vereb G, Remenár É, Tóvári J.   +14 more
europepmc   +1 more source

Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells [PDF]

, 2017
et al,, Ghasemi, Reza
core   +2 more sources

Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance. [PDF]

J Cancer Res Clin Oncol, 2023
Torlot L, Jarzab A, Albert J, Pók-Udvari Á, Stahler A, Holch JW, Gerlinger M, Heinemann V, Klauschen F, Kirchner T, Kumbrink J, Küster B, Jung A.   +12 more
europepmc   +1 more source

EBV-induced upregulation of CD55 reduces the efficacy of cetuximab treatment in nasopharyngeal carcinoma

Journal of Translational Medicine
Cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, has been shown to improve survival in nasopharyngeal carcinoma (NPC) patients. However, a correlation between the expression of EGFR and the response to cetuximab has not been observed,
Qian Zhu, Xiao-Bing Duan, Hao Hu, Rui You, Tian-Liang Xia, Tao Yu, Tong Xiang, Ming-Yuan Chen   +7 more
doaj   +1 more source

Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression. [PDF]

Exp Ther Med, 2023
Wei Z, Wang Z, Chai Q, Li Z, Zhang M, Zhang Y, Zhang L, Tang Q, Zhu H, Sui H.   +9 more
europepmc   +1 more source

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells. [PDF]

Toxins (Basel), 2023
Landi N, Ciaramella V, Ragucci S, Chambery A, Ciardiello F, Pedone PV, Troiani T, Di Maro A.   +7 more
europepmc   +1 more source

PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer. [PDF]

Cell Mol Gastroenterol Hepatol, 2022
Luo M, Huang Z, Yang X, Chen Y, Jiang J, Zhang L, Zhou L, Qin S, Jin P, Fu S, Peng L, Li B, Fang Y, Pu W, Gong Y, Liu Y, Ren Z, Liu QL, Wang C, Xiao F, He D, Zhang H, Li C, Xu H, Dai L, Peng Y, Zhou ZG, Huang C, Chen HN.   +28 more
europepmc   +1 more source

Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer. [PDF]

Clin Cancer Res, 2022
Cruz-Duarte R, Rebelo de Almeida C, Negrão M, Fernandes A, Borralho P, Sobral D, Gallego-Paez LM, Machado D, Gramaça J, Vílchez J, Xavier AT, Ferreira MG, Miranda AR, Mansinho H, Brito MJ, Pacheco TR, Abreu C, Lucia-Costa A, Mansinho A, Fior R, Costa L, Martins M.   +21 more
europepmc   +1 more source